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Background: This study was carried out a network meta-analysis of evidence from randomized controlled trials
(RCTs) to evaluate stent-related discomfort in patients with alfuzosin or tamsulosin versus placebo.
Methods: Relevant RCTs were identified from electronic databases. The proceedings of appropriate meetings were
also searched. Seven articles on the basis of RCTs were included in our meta-analysis. Using pairwise and network
meta-analyses, comparisons were made by qualitative and quantitative syntheses. Evaluation was performed with
the Ureteric Stent Symptoms Questionnaire to assess the urinary symptom score (USS) and body pain score (BPS).
Results: One of the seven RCTs was at moderate risk of bias for all quality criteria; two studies had a high risk of bias.
In the network meta-analysis, both alfuzosin (mean difference [MD];−4.85, 95 % confidence interval [CI];−8.53–−1.33)
and tamsulosin (MD;−8.84, 95 % CI;−13.08–−4.31) showed lower scores compared with placebo; however, the
difference in USS for alfuzosin versus tamsulosin was not significant (MD; 3.99, 95 % CI;−1.23–9.04). Alfuzosin
(MD;−5.71, 95 % CI;−11.32–−0.52) and tamsulosin (MD;−7.77, 95 % CI;−13.68–−2.14) showed lower scores for BPS
compared with placebo; however, the MD between alfuzosin and tamsulosin was not significant (MD; 2.12, 95 %
CI;−4.62–8.72). In the rank-probability test, tamsulosin ranked highest for USS and BPS, and alfuzosin was second.
Conclusion: The alpha-blockers significantly decreased USS and BPS in comparison with placebo. Tamsulosin
might be more effective than alfuzosin.
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In 1978, the ureteral double-J stent was first described by
Finney et al. [1, 2]. Ureteral double-J stent insertion has
been one of the most common urologic procedures; how-
ever, indwelling stents are often accompanied by signifi-
cant morbidity including voiding and storage symptoms,
flank pain, hematuria, and infection [3]. Symptoms of
stent discomfort, including bladder irritation symptoms
and flank pain or discomfort, are generally treated with* Correspondence: joouro@yuhs.ac
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creativecommons.org/publicdomain/zero/1.0/oral analgesics, such as narcotics and antiinflammatory
medications; however these medications are only moder-
ately effective. Alpha-blockers alleviate bladder irritation
due to stents, resulting in reduced incidence of dysuria,
frequency, and pain compared to placebo [4]. Ureteral
stent discomfort may be due to spasms of the ureteral
smooth muscle that surrounds the indwelling foreign ob-
ject and may run the length of the ureter. Further, irrita-
tion of the trigone, which also has alpha-1d receptors,
may be caused by the intravesical lower coil of the stent.
Alternatively, voiding may increase pressure on the renal
pelvis and cause discomfort [5]. Several studies have inves-
tigated if alpha-blockers can alleviate symptoms related to
stent placement [6]. In 2011, Lamb et al. reported a pair-icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Kwon et al. BMC Urology  (2015) 15:55 Page 2 of 10wise meta-analysis of randomized controlled trials (RCTs)
indicating that orally administrated alpha-blockers reduce
stent-related discomfort and storage symptoms as evalu-
ated by the Ureteric Stent Symptoms Questionnaire
(USSQ) [7].
Newly introduced network meta-analysis is a meta-
analysis in which multiple treatments are compared using
direct comparisons of interventions within RCTs and indir-
ect comparisons across trials based on a common compara-
tor [8–10]. The present systematic review and network
meta-analysis examined available RCTs to study the effects
of alpha-blockers on stent-related symptoms.Methods
Inclusion criteria
Published RCTs that accorded with the following criteria
were included. (i) The design of study had an assessment
for alpha-blockers to treat ureteral stent discomfort. (ii) A
match was performed between the baseline characteristics
of patients from two groups, including the total number of
subjects and the values of each index. (iii) Alpha-blockers
were analyzed with standard therapy or a placebo group.
(iv) Standard indications for ureteral stenting, such as stone
treatment, ureteroscopic procedures, and ureteral surgery
including pyeloplasty, were accepted. (v) Endpoint outcome
parameters were described using USSQ, including urinary
symptom score (USS) and body pain score (BPS). (vi) The
full text of the study was available in English. This report
was prepared in compliance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement (accessible at http://www.prisma-statement.org/).Search strategy
A literature search of all publications before 31 January
2014 was performed in EMBASE and PubMed. Add-
itionally, a cross-reference search of eligible articles was
performed to check studies that were not found during
the computerized search. Combinations of the following
MeSH terms and keywords were used: tamsulosin, alfu-
zosin, doxazosin, terazosin, silodosin, prazosin, alpha,
stent, discomfort, pain, complication, ureter, ureteral,
ureteric, and randomized controlled trial.Extraction of data
A researcher (JKK) screened all titles and abstracts iden-
tified by the search strategy. Other two researchers (JYL
and DHK) independently evaluated the full text of each
paper to determine whether a paper met the inclusion
criteria. Disagreements were resolved by discussion until
a consensus was reached or by arbitration mediated by
another researcher (KSC).Quality assessment for each study
After the final group of papers was agreed on, two re-
searchers (JYL and JKK) independently evaluated the
quality of each article. The Cochrane’s risk of bias as a
quality assessment tool for RCTs were used. The assess-
ment included assigning a judgment of “yes,” “no,” or
“unclear” for each domain to designate a low, high, or
unclear risk of bias, respectively. If one or no domain
was deemed “unclear” or “no,” the study was classified
as having a low risk of bias. If four or more domains
were deemed “unclear” or “no,” the study was classified
as having a high risk of bias. If two or three domains
were deemed “unclear” or “no,” the study was classified
as having a moderate risk of bias [11]. Quality assess-
ment was performed with Review Manager 5 (RevMan
5.2.11, Cochrane Collaboration, Oxford, UK).
Heterogeneity tests
Heterogeneity on included studies was examinated using
the Q statistic and Higgins’ I2 statistic [12]. Higgins’ I2
measures the percentage of total variation due to hetero-
geneity rather than chance across studies. Higgins’ I2
was calculated as follows:
I2 ¼ Q‐df
Q
 100%;
in which “Q” was Cochran’s heterogeneity statistic, and
“df” was the degrees of freedom.
An I2 ≥ 50 % was considered to represent substantial
heterogeneity. For the Q statistic, heterogeneity was
deemed to be significant for p less than 0.10 [13]. If there
was evidence of heterogeneity, the data were analyzed
using a random-effects model. A summary estimate of the
test sensitivity was obtained with 95 % confidence inter-
vals (CIs) after secondary examination of heterogeneity in
the random-effects model using radial plots [14]. Studies
in which positive results were confirmed were assessed
with a pooled specificity with 95 % CIs.
Statistical analysis
Outcome variables measured at specific time points were
compared in terms of mean differences with 95 % CIs
using a network meta-analysis. Analyses were based on
non-informative priors for effect sizes and precision.
Convergence and lack of auto-correlation were con-
firmed after four chains and a 50,000-simulation burn-in
phase; finally, direct probability statements were derived
from an additional 100,000-simulation phase. The probabil-
ity that each group had the lowest rate of clinical events
was assessed by Bayesian Markov Chain Monte Carlo mod-
eling. Sensitivity analyses were performed by repeating the
main computations with a fixed-effect method. Model fit
was appraised by computing and comparing estimates for
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analyses were performed with Review Manager 5 and R (R
version 3.0.3, R Foundation for Statistical Computing,
Vienna, Austria; http://www.r-project.org) and the meta-
for and gemtc packages for pair-wise and network meta-
analyses.
Results
Eligible studies
The database search retrieved 21 articles covering 88 stud-
ies for potential inclusion in the meta-analysis. Fourteen
articles were excluded based on the inclusion/exclusion
criteria; eight of the fourteen articles were retrospective
models, and three articles were reported with different
tools and variables. The other three articles were excluded,
because they did not report final results. Using using pair-
wise and network meta-analyses, the remaining seven arti-
cles were included in the qualitative and quantitative
syntheses (Fig. 1).
Data corresponding to confounding factors in each
study are summarized in Table 1. Four studies includedFig. 1 Flow diagram of evidence acquisition. Seven studies were ultimately
and network meta-analysesoutcome comparisons between alfuzosin versus placebo
[15–18]. Two trials reported on therapeutic outcomes
of tamsulosin versus placebo [19, 20], and a three-arm
trial compared outcomes of alfuzosin, tamsulosin, and
placebo [21].
Quality assessment
Figures 2 and 3 present the details of quality assessment,
as measured by the Cochrane Collaboration risk-of-bias
tool. Four trials exhibited a low risk of bias for all quality
criteria, and two studies were classified as having a high
risk of bias (Table 1). The most common risk factor for
quality assessment was the risk of blinding of outcome
assessment; the second most common concerns were al-
location concealment and blinding participants and
personnel.
Heterogeneity assessment
Forest plots of pairwise meta-analyses are demonstrated
in Fig. 4. A heterogeneity test for USS showed the fol-
lowing: χ2 = 96.43 with 7 df (P < 0.001) and I2 = 93 % inincluded in the qualitative and quantitative syntheses using pairwise
Table 1 Enrolled studies for this meta-analysis
Stent Stone
Study Study
design
N Tx P Alpha-
blocker
Analgesic Duration
(day)
Type Size Length Indication Size
(mm)
Location Measure Quality
assessment-risk
bias
Tx P
Beddingfield
et al.[15]
RCT 55 26 29 Alfuzosin On
demand
10 NA NA Adjusted Post URS 6.35 7.2 55 % renal USSQ Low
- urinary
symptom score
10 mg
- body pain
score
- general health
score
25 % renal/
ureteric
- work
performance
score
20 %
ureteric
- sexual health
score
Damiano
et al.[20]
RCT 75 38 37 Tamsulosin On
demand
14 PU 7 Fr Adjusted Post URS NA NA NA USSQ Intermediate
0.4 mg - urinary
symptom score
- body pain
score
Deliveliotis
et al.[16]
RCT 100 50 50 Alfuzosin On
demand
28 PU 5 Fr Adjusted Conservative treatment for stone,
<10 mm, hydronephrosis
7.6 7.1 19 upper USSQ Low
23 mid - urinary
symptom score
10 mg 48 lower - body pain
score
- general health
score
- sexual health
score
Dellis
et al.[21]
RCT 150 100 50* Alfuzosin On
demand
28 NA 6 Fr Adjusted Post ESWL, URS NA NA NA USSQ Low
- urinary
symptom score
10 mg
Tamsulosin - body pain
score
0.4 mg - general health
score
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Table 1 Enrolled studies for this meta-analysis (Continued)
- work
performance
score
- sexual health
score
Nazim
et al.[17]
RCT 130 65 65 Alfuzosin On
demand
7 PU 4.7 Fr
6 Fr
NA Post URS NA NA 40 upper VAS High
28 mid USSQ
10 mg 62 lower - urinary
symptom score
- body pain
score
Park et al.[18] RCT 32 20 12 Alfuzosin NA 42 PU 6 Fr Adjusted Post URS, PCNL, Lap Pyelo, endo-
ureterotomy
NA NA NA USSQ High
- urinary
symptom score
- body pain
score
10 mg
- general health
score
- work
performance
score
- sexual health
score
Wang
et al.[19]
RCT 154 79 75 Tamsulosin On
demand
7 Sil 7 Fr Adjusted Post URS 9 9.4 16 upper USSQ Low
49 mid - urinary
symptom score
0.4 mg 89 lower - body pain
score
- general health
score
- work
performance
score
- sexual health
score
Adjusted, stent length is height adjusted; NA, not available; Tx, Treatment group, P, placebo; PU, Polyurethane; Sil, Silcone;USSQ, Ureteric Stent Symptom Questionnaire; VAS, visual analogue scale; URS, ureteroscopy;
PCNL, percutaneous nephrolithotomy; Lap Pyelo, laparoscopic pyeloplasty
*50 patients received alfuzosin 10 mg, and another 50 patients received tamsulosin 0.4 mg
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Fig. 2 Risk of bias graph. We reviewed the risk of bias in each study
included in this meta-analysis and presented the results as percentages.
Four trials exhibited a low risk of bias for all quality criteria, and two studies
were classified as having a high risk of bias
Fig. 3 Risk of bias summary. We reviewed the risk of bias in each of the stu
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tamsulosin versus placebo. Notable heterogeneities were
detected in the analyses of all studies; thus, random-
effects models were used to further assess these vari-
ables. In the analysis of BPS, a heterogeneity test demon-
strated homogeneity with χ2 = 44.66 with 8 df (P < 0.001)
and I2 = 82 %. Pairwise meta-analyses with random-
effects models were also performed. None of the vari-
ables demonstrated heterogeneity in radial plots after
selecting effect models for USS and BPS (Fig. 5).
Publication bias
Funnel plots from pairwise meta-analyses are demon-
strated in Fig. 6; however, with few studies, it was difficult
to assess publication bias, although some degree of bias is
suspected.
Pairwise meta-analysis for urinary symptom and body
pain scores
The forest plot using the random-effects model demom-
strated an MD of −5.69 for USS (95 % CI [−8.84–−2.53], P
< 0.001) between alpha-blockers and placebo (Fig. 4a). In
subanalyses, both alfuzosin (MD; −4.12, 95 % CI [−5.51–
−2.73], P < 0.001) and tamsulosin (MD; −7.83, 95 % CI
[−14.35–−1.31], P= 0.02) had low MDs versus placebo. Ac-
cording to the forest plot for BPS, alpha-blockers were su-
perior to placebo, with an MD of −6.20 (95 % CI [−8.74–
−2.13], P < 0.001) (Fig. 4b). In the subanalysis of alfuzosin
versus placebo, alfuzosin showed an MD of −4.21 (95 % CI
[−5.56–−2.85], P < 0.001). Between tamsulosin and placebo,
the random-effects model demonstrated an MD of −7.71
(95 % CI [−13.28–−2.13], P= 0.007) for BSP.
Network meta-analysis for urinary symptom and body
pain scores
Alfuzosin had a lower In USS than that of placebo (MD;
−4.85, 95 % CI [−8.53–−1.33]). Tamsulosin also had a
lower score than that of placebo (MD; −8.84, 95 % CI
[−13.08–−4.31]. However, there was not a significant
difference in MD between alfuzosin and tamsulosindies included in this meta-analysis
Fig. 4 Pairwise meta-analysis. (a) urinary symptom score (b) body pain score
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[−1.23–9.04]). There were significant differences in the
BPS achieved with alfuzosin versus placebo (MD; −5.71,
95 % CI [−11.32–−0.52]) and in tamsulosin versus pla-
cebo (MD; −7.77, 95 % CI [−13.68–−2.14]). Comparison
of the BPS achieved with tamsulosin versus alfuzosin
showed an MD of 2.12 (95 % CI [−4.62–8.72]), which
was not significant (Fig. 7). In the rank-probability test,
tamsulosin had the highest rank for USS, followed by
alfuzosin. Tamsulosin was also ranked highest for BPS
in the rank-probability test, followed by alfuzosin. The
placebo was ranked lowest for USS and BPS (Fig. 8).
Discussion and conclusion
Recently, two pair-wise meta-analyses of alpha-blockers in
patients with ureteral stent discomfort were published.
Yakoubi et al. conducted a meta-analysis of four RCTs
[22]. However, they did not distinguish the types of alpha-
blockers analyzed by each domain. Alpha-blockers re-
duced the scores for urinary symptoms, body pain, and
general health index score but did not achieve significantchanges in quality of work, sexual matters, or scores for
additional problems. However, there were limits, as few
studies were analyzed; in particular, only three studies
were analyzed for quality of work and two for additional
problems. Lamb et al. conducted a meta-analysis of five
RCTs by distinguishing between alfuzosin and tamsulosin
[7]; however, there was possible error in the effects-model
with regards to heterogeneity. However, these meta-
analyses showed decreased scores for both urinary symp-
toms and body pain after use of alpha-blockers.
More recently, Dellis et al. evaluated the effects of two
different alpha-blockers for improving symptoms and
quality of life in patients with indwelling ureteral stents
in an RCT [21]. They prescribed alfuzosin, tamsulosin,
or placebo to 50 patients and examined USSQ accord-
ingly. Patients who received alpha-blockers had signifi-
cantly decreased urinary symptoms, body pain, general
health index, and sexual life scores compared to those of
the control group. However, there was no difference in
the quality of work score. Further, there was no differ-
ence between the alpha-blocker groups.
Fig. 5 Radial plots. None of the variables demonstrated heterogeneity
after selecting effect models for each variable in the radial plots. (a) urinary
symptom score (b) body pain score
Fig. 6 Funnel plots. (a) urinary symptom score (b) body pain score. It was
degree of bias is suspected
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tween tamsulosin and alfuzosin in alleviating stent dis-
comfort by comparing the effectiveness of alpha-blockers
to placebo in seven RCTs based on urinary symptoms and
body pain scores. In most studies, continuous treatment
had been carried out before the removal of ureter stents.
We divided alpha-blockers into alfuzosin and tamsulosin
to conduct subgroup and network meta-analyses. In the
subgroup analysis, two alpha-blockers appeared to signifi-
cantly decrease urinary symptoms and body pain scores
compared to those of the placebo. There was no statistical
significance between alfuzosin and tamsulosin in network
meta-analysis both in urinary symptoms and body pain
scores, which was consistent with the results of previous
studies. However, after conducting network meta-analysis
using a rank-probability test, the effectiveness of tamsulo-
sin appeared to be better than that of alfuzosin in both
urinary symptoms and body pain scores (Fig. 8).
We suggested that the difference in efficacy between the
two alpha-blockers arises from the physiologic character-
istics of ureteral receptor distribution. The ureter contains
two continuous thin muscle layers with a loosely spiraled
internal layer and a more tightly spiraled external layer. A
third outer longitudinal layer is located in the lower third
of the ureter. The lower ureter is consisted of transitional
epithelium, a connective tissue layer, and three layers of
smooth muscle [23]. Peristalsis of ureter is initiated by
spontaneous activity of the renal pelvis pacemaker cell
and is essentially regulated by the myogenic mechanism
and neurogenic factors; electrical and mechanical activities
are conducted to inactive distal regions [24]. The histo-
logic characteristics of the three smooth muscle layers in
the lower portion of ureter and the denser innervation of
the lower portion of ureter have become subjects of re-
search interest. The alpha-1d receptor has the highestdifficult to assess publication bias with few studies, although some
Fig. 7 Network meta-analysis. (a) urinary symptom score (b) body pain score. Alfuzosin and tamsulosin had a lower score both in USS and BPS
than in the placebo. However, there was not a significant difference in MD between alfuzosin and tamsulosin according to network meta-analysis
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type selective alpha-1a and alpha-1d blocker, whereas alfu-
zosin is a subtype non-selective alpha-1 blocker [25]. The
two alpha-blockers may elicit different levels of efficacy
due to differences in selectivity and the distribution of the
alpha-1d receptor in the lower ureter. However, it remains
unclear if subtype selectivity makes a significant contribu-
tion to the differences in efficacy of alpha-blockers. In the
near future, prospective trials should compare several
alpha-blockers, including silodosin and naftopidil, to con-
firm our results.
A limitation of our study was that only two subdomains
were included, urinary symptoms and body pain scores, as
not all the RCTs involved in this study had available USSQFig. 8 Rank-probability test of network meta-analyses. (a) urinary symptom score
alfuzosin. Tamsulosin was also ranked highest for BPS in the rank-probability test,domains besides urinary symptoms and body pain scores
(Table 1). These may cause a bias in the efficacy of the
two alpha-blockers, which can be influenced by other
symptoms and quality of life. All RCTs included in the
present study used USSQ, which comprehensively assesses
not only urinary symptoms and pain, but also sexual
symptoms and quality of life. Although urinary symptoms
and pain are the most problematic among stent-related
symptoms of discomfort, low abdominal pain or discom-
fort, infection, and hematuria are also bothersome to pa-
tients. Furthermore, alpha-blockers can cause side effects
on the central nervous system, sexual function, ejaculatory
function, and cardiovascular system [26]. Therefore, it is
important to compare not only the efficacy between the(b) body pain score. Tamsulosin had the highest rank for USS, followed by
followed by alfuzosin. The placebo was ranked lowest for USS and BPS
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parison of USSQ domains may also need to be considered.
Some degree of publication bias was also a limitation of this
study. However, Sutton et al. reviewed 48 articles from the
Cochrane Database of Systematic Reviews and showed
publication or related biases were common within the sam-
ple of meta-analyses assessed [27]. Moreover, they found
that these biases did not affect the conclusions in most
cases. Another limitation was that we did not take into con-
sideration the possible effects of stent factors on stent dis-
comfort. Although six out of seven RCTs reported that
stent insertion was performed with height adjustment and
the differences of stent materials were also considered,
there was no consideration as to whether the stent was
placed correctly or not. Lee et al. [28]. reported that only
storage symptoms of the tamsulosin group were signifi-
cantly lower than those of the analgesic group in the appro-
priate stent position. However, this medication effect was
not observed in the inappropriate stent position group, and
total IPSS and storage symptom scores were significantly
higher than in the appropriate stent position group. The ap-
propriate stent position might be one of the points to be
considered when conducting the research on stent
discomfort.
Conclusions
Ureteral stent-related symptoms are effectively alleviated
with alpha-blockers. Tamsulosin might be more effective
than alfuzosin. However, additional randomized controlled
trials with alfuzosin and tamsulosin need to be performed
for patients with ureteral stents.
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